Stroke Management in Patients with Diabetes mellitus or Metabolic Syndromes

Plenary Symposium at the 14th European Stroke Conference, Bologna, Italy, May 26, 2005

Supported by an unrestricted educational grant by sanofi-aventis and Bristol-Myers Squibb

Editor
J. Bogousslavsky, Lausanne

13 figures and 10 tables, 2005
This supplement is made possible through a grant from sanofi-aventis and Bristol-Myers Squibb Company.

Information is provided for medical and scientific purposes only, neither sanofi-aventis nor Bristol-Myers Squibb recommends the use of clopidogrel in any manner inconsistent with that described in the full prescribing information available in your country.
Contents

1 Preface
   Bogousslavsky, J. (Lausanne)

2 The Metabolic Syndrome and Type 2 Diabetes: Epidemiological Figures and Country Specificities
   Procopiou, M.; Philippe, J. (Geneva)

9 Acute Stroke and Diabetes
   Lees, K.R.; Walters, M.R. (Glasgow)

15 Secondary Prevention of Stroke with Antiplatelet Agents in Patients with Diabetes mellitus
   Piechowski-Jozwiak, B. (Lausanne/Warsaw); Maulaz, A.; Bogousslavsky, J. (Lausanne)

24 Prevention of Stroke in Patients with Diabetes mellitus and the Metabolic Syndrome
   Rothwell, P.M. (Oxford)